论文部分内容阅读
目的:评价小檗碱对小鼠非酒精性脂肪性肝病程序性坏死的影响及其与腺苷酸活化蛋白激酶(AMPK)/转录活化因子6(STAT6)通路的关系。方法:将25只8周龄雄性C57BL/6N小鼠分为对照组、脂肪肝组、小檗碱治疗组(200 mg·kgn -1·dn -1)、AMPK抑制剂Compound C治疗组(0.2 mg·kgn -1·dn -1)、STAT6抑制剂AS1517499治疗组(10 mg·kgn -1·dn -1)。第12周末给小鼠称重并采集血清检测天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、三酰甘油、肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β)水平；留取肝脏组织称重并检测丙二醛和超氧化物歧化酶浓度，并予HE、Masson和油红O染色；Western印迹法检测程序性坏死蛋白受体相互作用蛋白激酶3(RIPK3)、磷酸化(p-)混合系列蛋白酶样结构域(MLKL)及通路蛋白AMPK、p-AMPK、p-STAT6的表达。n 结果:与对照组相比，脂肪肝组肝质量、肝指数、AST、ALT、三酰甘油、TNF-α、IL-1β、氧化应激程度明显加重(n P<0.05)，肝组织充满空泡样改变及炎性细胞浸润，可见广泛分布的红色脂滴和明显蓝色纤维，RIPK3及p-MLKL表达上调(n P<0.05)，p-AMPK和p-STAT6水平降低(n P<0.05)；与脂肪肝组相比，小檗碱干预可明显降低小鼠肝质量与肝指数，改善肝功能，降低血脂水平、促炎因子表达以及氧化应激水平，肝组织脂肪变性及纤维化程度明显减轻，RIPK3及p-MLKL表达下调(n P<0.05)，p-AMPK和p-STAT6水平显著增加(n P<0.05)；与小檗碱治疗组相比，给予AMPK和STAT6抑制剂处理均可抵消小檗碱对脂肪肝的保护效应，RIPK3及p-MLKL表达增加(n P0.05)。n 结论:小檗碱可激活AMPK/STAT6通路，抑制肝细胞程序性坏死，发挥对小鼠非酒精性脂肪性肝病的保护作用。“,”Objective:To evaluate the effects of berberine on necroptosis of non-alcoholic fatty liver disease in mice and its relationship with adenosine monophosphate-activated protein kinase(AMPK)/ signal transducer and activator of transcription 6(STAT6) pathway.Methods:Twenty-five 8-week-old male C57BL/6N mice were divided into control group, steatotic liver group, berberine treatment group(200 mg·kgn -1·dn -1), AMPK inhibitor Compound C treatment group(0.2 mg·kgn -1·dn -1), and STAT6 inhibitor AS1517499 treatment group(10 mg·kgn -1·dn -1). After 12 weeks of intervention, the mice and liver tissue were weighed, and serum aspartate aminotransferase(AST), alanine aminotransferase(ALT), triglyceride, tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β) as well as liver malondialdehyde and superoxide dismutase were measured; liver tissue HE, Masson, and oil red O staining were performed. Western blotting was used to detect the expressions of necroptosis related proteins[receptor interaction protein kinase 3(RIPK3), phosphorylated(p-) mixed lineage kinase domain-like(MLKL)], AMPK, p-AMPK, and p-STAT6.n Results:Compared with control group, the steatotic liver group had higher quality of liver and liver index, and higher levels of serum AST, ALT, triglyceride, TNF-α, IL-1β, and oxidative stress(n P<0.05); Liver tissue was full of cavity changes and inflammatory cell infiltration, widely distributed red lipid droplets and obvious blue fiber dyeing; The expressions of RIPK3 and p-MLKL were up-regulated (n P<0.05), but the levels of p-AMPK and p-STAT6 were relatively reduced (n P<0.05). Compared with the steatotic liver group, berberine intervention decreased liver quality and liver index, improved liver function, reduced blood lipid levels, pro-inflammatory factor expression and oxidative stress level, and significantly alleviated the degree of liver steatosis and fibrosis, the levels of RIPK3 and p-MLKL (n P<0.05), while the expressions of p-AMPK and p-STAT6 were increased significantly (n P<0.05). As compared with the berberine treatment, AMPK and STAT6 inhibitor treatment could offset the protective effect of berberine on steatotic liver, moreover, the expressions of RIPK3 and p-MLKL were increased (n P0.05).n Conclusion:Berberine can activate AMPK/STAT6 pathway to inhibit the necroptosis of hepatocyte, thus plays a protective role on non-alcoholic fatty liver disease in mice.